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Background: Cytochrome P450 2S1 (CYP2S1) is an orphan P450 with an unknown biological function. Data from
our laboratory and others suggest that CYP2S1 may have an important physiological role in modulating the
synthesis and metabolism of bioactive lipids including prostaglandins and retinoids. CYP2S1 expression is elevated
in multiple epithelial-derived cancers as well as in the chronic hyperproliferative disease psoriasis. Whether CYP2S1
expression in proliferative disease is protective, detrimental, or neutral to disease progression remains to be
determined. Two human bronchial epithelial cells (BEAS-2B) were constructed to represent chronic depletion of
CYP2S1 using short-hairpin RNA (shRNA) silencing directed toward the 3’UTR (759) and exon 3 (984) of the CYP2S1
gene and compared with a non-targeting shRNA control (SCRAM). Both CYP2S1 mRNA and protein were depleted
by approximately 75% in stable cell lines derived from both targeted shRNA constructs (759 and 984). To elucidate
the biological significance of CYP2S1, we analyzed transcriptome alterations in response to CYP2S1 depletion in
human lung cells.
Results: RNA-sequencing (RNA-seq) analysis was performed to compare the transcriptome of the control (SCRAM)
and the CYP2S1-depleted (759) BEAS-2B cell lines. Transcriptomes of the replicates from the two cell lines were
found to be distinct populations as determined using Principal Component Analysis and hierarchical clustering.
Approximately 1000 genes were differentially expressed in response to CYP2S1 depletion. Consistent with our
previous phenotypes, DAVID analysis revealed altered regulation in key pathways implicated in cell proliferation and
migration. Transcriptomic profiles were also consistent with the metabolism of proposed endogenous substrates.
Pathway analysis also revealed significant expression changes within mTOR signaling, a critical pathway in cell
growth. To determine whether these changes manifest as altered cell size, cell diameter and volume were
calculated, revealing that CYP2S1 depletion promotes cell growth in BEAS-2B cells.
Conclusions: These data suggest that pathway analysis of sequence-based gene expression is a powerful method
to identify pathways and phenotypic alterations in response to changes in orphan enzyme expression. Our results
suggest a novel role for CYP2S1-mediated metabolism in modulating BEAS-2B cell size. These findings
warrant further studies on CYP2S1 regulated pathways to elucidate potential substrates of CYP2S1.
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Although the human genome was declared complete nearly
a decade ago [1] and many of the proteins linked to these
sequences have been identified, the challenge remains to
characterize the functional significance of these proteins. It
is particularly difficult to elucidate the metabolic activity of
enzymes with no known substrate or critical function. Cyto-
chrome P450s (CYPs) are heme-containing metabolic en-
zymes that typically catalyze the oxidation of endogenous
and xenobiotic chemical substrates. Although these enzymes
demonstrate a critical role in the metabolism of ~75% of all
xenobiotic substrates, less than half of these enzymes have
critical physiological functions [2-4]. A recent analysis of the
human genome revealed approximately 57 distinct human
CYPs [4]. Roughly one-quarter of these CYPs are classified
as orphans with little or no knowledge of their substrates
and physiological significance. One of the most recently
identified CYPs, Cytochrome P4502S1 (CYP2S1), was iden-
tified through a bioinformatics approach [5] and is among
these orphan P450s.
CYP2S1 is likely to play an important role in regulating
endogenous metabolism. CYP2S1 expression is sensitive to
regulation by endogenous and exogenous chemicals. Retin-
oic acid significantly elevated CYP2S1 at the mRNA and
protein level in a variety of human epithelial cells [6], in-
cluding human lung cells [7]. Oxygen deprivation within
cultured cells also resulted in significant elevation of
CYP2s1 mRNA within mouse hepatoma Hepa-1 cells [8];
however, a similar treatment in human monocytes did not
alter expression [9]. CYP2S1 expression was elevated in re-
sponse to agonists of the arylhydrocarbon receptor, AhR,
including dioxin and 3-methylchloranthrene (3-MC) [10]
and components of cigarette smoke [11]. Conversely, anti-
inflammatory glucocorticoid agonist treatment of human
lung cells at physiologically relevant concentrations signifi-
cantly depleted CYP2S1 mRNA through epigenetic modu-
lation of CYP2S1 [12]. CYP2S1 was also elevated in chronic
hyperproliferative diseases, including psoriasis [6] as well as
multiple epithelial cancers [13-16]. It is likely that both
transient and chronic changes in CYP2S1 expression alter
metabolic activation of potential endogenous substrates
and may reveal an important physiological role for
CYP2S1.
Although it has been shown to effectively metabolize
cancer therapeutics of the anthraquinone (AQ4N) [17,18]
and benzothiazole family (GW610 and SF203) [19],
CYP2S1 is still considered an orphan with no known en-
dogenous substrates. Candidate substrates have been iden-
tified and include the bioactive lipids all-trans retinoic
acid (RA) [6,20,21] and metabolites of the arachidonic
acid inflammatory cascade (in particular metabolites of
the cyclooxygenase (prostaglandins) and lipoxygenase
(HETES) pathways [9,22]. CYP2S1-mediated metabolism
of these lipids appears to require atypical metabolism(peroxide shunt pathway) and whether CYP2S1 contrib-
utes to the metabolism of these bioactive lipids is contro-
versial [18]. However, in vitro cellular assays in human
and rodent cells appear to be consistent with metabolism
of these endogenous substrates [9,22,23]. Previous work in
our laboratory, examined the impact of CYP2S1 depletion
on human bronchial epithelial (BEAS-2B) cells [23]. De-
pletion of CYP2S1 in these cells led to enhanced cell pro-
liferation and migration. Cell proliferation was, in part,
attributed to modulation of arachidonic acid cascade,
resulting in elevated levels of the inflammatory prostaglan-
din (PGE2) [23]. The etiology of the change in migration,
however, is still unclear.
Elucidating the physiological significance of an
orphan cytochrome P450s is a complicated process
hampered by difficulties in isolation and purification of
CYPs as well as identifying possible substrates from a
myriad of potential chemicals. Historically, a trial-and-
error approach has been used to identify possible
substrates. However, this approach is time and resource
intensive and neglects chemicals outside of the chem-
ical library. Recently, the Guengerich lab has success-
fully utilized advances in methodology and mass
spectrometry analysis to identify endogenous sub-
strates for a number of cytochrome P450s, including
orphans [24,25]. This approach is a significant advance
in identification of novel endogenous substrates. How-
ever, it does not directly demonstrate the physiological
impact of changes in P450 expression within human
cells. To elucidate the physiological significance of al-
terations in P450 expression on biological pathways, we
utilize next generation sequencing as a novel, unbiased
approach to identify transcriptional changes in bio-
logical pathways within human cells. Specifically, we
compare the transcriptomic profiles of two human
bronchial epithelial (BEAS-2B) cell lines with differen-
tial CYP2S1 expression: CYP2S1 depleted (759) vs.
control (SCRAM). Previous work in our lab demon-
strated that CYP2S1 depleted cells enhanced cell prolif-
eration and migration [23]. We illustrate how pathway
analysis of sequence-based differential expression
results identified the molecular pathways perturbed in
response to CYP2S1 depletion, provided insight into
unexpected modes of action, and informed follow up
experiments. Here we report how transcriptomic
profiles are consistent with published phenotypes and
proposed endogenous metabolism. Additionally, our
results reveal novel changes in the mTOR signaling
pathway, which has been linked to cell size [26]. We
pursued this phenotype experimentally and confirmed
a significant increase in cellular diameter and volume
in CYP2S1 depleted cells, suggesting a previously un-
known role for CYP2S1-mediated metabolism in the
regulation of cell growth.
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RNA-sequencing Analysis of CYP2S1 depleted human
bronchial epithelial cells (BEAS-2B)
To determine whether alterations in the transcriptomic
profiles would reveal the functional significance of CYP2S1
in human bronchial epithelial (BEAS-2B) cells, we per-
formed short hairpin RNA (shRNA) silencing using se-
quences targeting the 3’UTR (759) and exon3 (984) to
deplete CYP2S1 expression in BEAS-2B cells. The deple-
tion of CYP2S1 mRNA and protein was confirmed in com-
parison to non-targeted shRNA control (SCRAM) [23].
The clones exhibiting the greatest difference in CYP2S1
mRNA and protein expression (i.e. 759#7 and SCRAM#1)
were further analyzed using RNA-sequencing. Total
mRNA was isolated from three independent passages of
each of CYP2S1 depleted (759) samples and scrambled
controls (SCRAM) and prepared into 6 sequencing librar-
ies. Samples were sequenced on the Illumina HiSeq 2000
platform, yielding an average of 11,824,726 1×50 nt short
reads per sample. These filtered reads were aligned with
GSNAP [27] to the human reference genome (GRCh37),
binned by annotated gene coordinate, and uniquely aligning
reads were summated to generate read count-based gene
expression estimates. Principal Component Analysis and
hierarchical clustering as implemented in JMP Genomics
{6.0} were used to qualitatively assess transcriptome-wide
similarities among biological replicates and between geno-
types (759 vs. SCRAM). Principle Component Analysis re-
veals that the three biological replicates from each genotype
tightly cluster with one another and the largest aspect of
captured transcriptome variability separates samples based
on genotype. This low variability within genotype increases
our ability to find quantitative differences in gene expres-
sion that are truly attributable to differences in CYP2S1 ex-
pression (Figure 1-A,B).
To identify specific differentially regulated genes be-
tween CYP2S1 depleted (759) and scrambled control
(SCRAM) in human bronchial epithelial cells, we used
the negative binomial test of significance as imple-
mented in the Bioconductor package DESeq with signifi-
cance defined as an adjusted p-value ≤0.05 [27]
(Figure 1C). CYP2S1 depletion resulted in the increased
expression of 1159 genes while significantly reducing ex-
pression of 1326 genes. RNA-seq confirmed CYP2S1 de-
pletion of approximately 3-fold in these samples.
Quantitative PCR of CYP2S1 was performed (primers
used as previously described [23] on each of the three
biological replicates, and expressed relative to one of the
most stable housekeeping genes identified in our study,
b-actin (ACTB). The results demonstrate a high con-
cordance in quantification of relative CYP2S1 expression
between the two experimental methods (Figure 1D). A
comprehensive list of differentially expressed genes is in-
cluded in an additional file (Additional file 1).DAVID analysis reveals biological pathways associated
with previously published phenotypes
To identify biological pathways regulated in response to
CYP2S1 depletion in BEAS-2B, we performed pathway
analysis using the Database for Annotation, Visualization,
and Integrated Discovery (DAVID; http://david.abcc.ncifcrf.
gov) [28,29]. DAVID analysis was performed on differen-
tially expressed genes, identified using DESeq analysis (p <
0.01), with the additional criteria that the differences exhibit
at least a 2-fold change in expression. This further restric-
tion reduced the number of genes to 998 (430 up and 568
down). Functional annotations were available for 919 of
these genes. The annotations were listed in terms of Kyoto
Encyclopedia of Genes and Genomes (KEGG) pathways as
well as Gene Ontology (GO) terms. Differentially expressed
genes (p < 0.01) were used for KEGG pathway analysis and
revealed 17 statistically significantly enriched KEGG terms
(Table 1). The most highly significant KEGG terms [Modi-
fied Fisher Exact P value (EASE score) < 0.01] include cell
cycle, lysosome, apoptosis, and prostate cancer. Other
KEGG terms with a significant number (EASE score ≤0.05)
of genes altered in response to CYP2S1 depletion include
sphingolipid metabolism, TGFβ and mΤΟR signaling path-
ways. DAVID enrichment analysis was also performed with
GO biological process (BP) terms. Complete GO BP term
annotations are included in supplementary information
(Additional file 2). The top 30 GO BP terms are shown in
Figure 2. The top GO annotations included terms related
to cell adhesion (cell adhesion, biological adhesion, cell-cell
adhesion), cell proliferation (negative regulation of epithelial
cell proliferation, cell proliferation, regulation of epithelial
cell proliferation), and retinoic acid regulation (response to
vitamin, response to vitamin A, response to retinoic acid).
The identification of genes involved in cell proliferation and
adhesion are consistent with enhanced cell viability and mi-
gration phenotypes identified previously in these CYP2S1
depleted (759 and 984) BEAS-2B cells [23].
CYP2S1 depletion evokes changes in P450s that
metabolize bioactive lipids
CYP2S1 does not appear to be required for survival, since
the CYP2a (4/5) bgs-null mouse (which includes a CYP2s1
knockout) is both viable and fertile [30]. It is likely that there
is redundancy between CYP2S1 and other P450s in en-
dogenous metabolic substrates. Therefore the effect of
CYP2S1 depletion on CYP expression was determined. A
total of 57 CYPs were analyzed in this RNA-seq experiment.
The majority of CYPs (86%) were equally divided among
CYPs that were either not expressed (51%; base mean value
<1.5 read) or were not significantly altered in response to
CYP2S1 depletion (35%; p > 0.05). A total of 8 CYPs (14%)
were significantly altered in response to CYP2S1 (759) de-
pletion. Five of the eight exhibit at least a 2-fold increase
(CYP4F11, CYP2J2, CYP4Z1) or decrease (CYP2S1,
Figure 1 RNA sequencing data quality and verification of CYP2S1 depletion in human bronchial epithelial cells. A. Principal component
analysis shows significant differences between biological samples with normal (SCRAM, red) and reduced (759, blue) expression of CYP2S1.
B. Heat map analysis reveals similarities between the biological replicates within each condition. C The spots on the MA plot represent each
gene within the analysis. The x-axis displays the log2 basal expression for each gene, while the y-axis represents the log2 change in expression
relative to (SCRAM) control. FDR adjusted significant changes (p < 0.05) are represented as green dots. D. Comparison of CYP2S1 expression
normalized to ACTB using either RNA-seq (grey) or qPCR (white). ** represents significant differences (p < 0.01) between CYP2S1 expression in
SCRAM controls (no fill) and CYP2S1 depleted (vertical lines) cells.
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control (Table 2). Two of these enzymes (CYP4F11 and
CYP4Z1) are still considered orphans [2-4], although hy-
droxylation of bioactive lipids has been demonstrated in re-
cent studies [31,32]. Interestingly, each enzyme altered in
response to CYP2S1 depletion are involved in metabolism
of bioactive lipids including arachidonic acid (Table 2).
Pathway analysis for the synthesis and metabolism of
proposed lipids substrates
CYP2S1-mediated metabolism of endogenous substrates
remains controversial. However, there exists published
biochemical and cellular evidence to suggest CYP2S1
mediated metabolism of the bioactive lipids including
all-trans retinoic acid [6,20,21] as well as metabolic
products of the arachidonic acid metabolism [9,22,23].
Transcriptional responses were evaluated for eachpathway to determine whether physiological responses
to CYP2S1 depletion were consistent with its proposed
role in lipid metabolism.
Transcriptome analysis of retinol metabolism in CYP2S1
depleted cells
All-trans retinoic acid (RA) is transported to the cell as
retinol (Vitamin A) and converted to retinal via oxidore-
ductases (ADH and SDR). Retinal is subsequently bioac-
tivated to RA via retinal dehydrogenases (RALDHs) [35].
Once formed, RA is inactivated via P450 oxidation to a
variety of metabolites. The CYP26 family is the most ef-
fective at oxidizing RA [36-39]. Other CYPs’ (CYP1A,
CYP2ABC, CYP3A, CYP4A) oxidation and conjugation
of retinoic acid to multiple hydroxylated products as
well as the glucuronide conjugate via UDP glucuronosyl-
transferase (UGT2B7) [40], respectively, is believed to
Table 1 Statistically significant KEGG classifications of differentially expressed genes in CYP2S1 depleted cells
KEGG term Count %* P value (EASE score) Fold enrichment
Cell Cycle 32 1.18 7.96E-04 1.83
Lysosome 29 1.07 2.49E-03 1.77
Apoptosis 22 0.81 7.43E-03 1.80
Prostate cancer 22 0.81 9.73E-03 1.76
Sphingolipid metabolism 12 0.44 1.52E-02 2.19
TGF-beta signaling pathway 21 0.78 1.53E-02 1.72
Nucleotide excision repair 12 0.44 3.62E-02 1.95
Pancreatic cancer 17 0.63 3.77E-02 1.68
N-Glycan biosynthesis 12 0.44 4.86E-02 1.86
mTOR signaling pathway 13 0.48 5.17E-02 1.78
Aminoacyl-tRNA biosynthesis 11 0.41 5.20E-02 1.91
Glycine serine and threonine metabolism 9 0.33 5.85E-02 2.07
Bladder cancer 11 0.41 6.01E-02 1.87
Pathways in cancer 57 2.11 6.03E-02 1.24
Glutathione metabolism 12 0.44 8.14E-02 1.71
Nitrogen metabolism 7 0.26 9.14E-02 2.17
Non-homologous end-joining 5 0.19 9.65E-02 2.74
*Indicates the percentage of genes in each pathway from 2702 genes mapped to KEGG.
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yielded contradictory results that either demonstrate
[6,20] or fail to show [17,18] CYP2S1-mediated metabol-
ism of RA. However, CYP2S1 expression within a cellu-
lar context in both chinese hamster ovary (CHO) cells
and human keratinocytes (HaCaT) cells demonstrate
that CYP2S1 contributes to retinoic acid metabolism in
cells [21]. To function, RA is shuttled to either cellular
retinoic acid binding protein (CRABPII) or fatty acid
binding proteins (FABP5) [41], depending on their ex-
pression levels within the cell. Once bound, RA is deliv-
ered by CRABP and FABP5 to retinoic acid receptor
(RAR) or peroxisome proliferating receptor (PPAR), re-
spectively, where it alters transcription of numerous
downstream targets.
According to the RNA-seq data, CYP2S1 depletion
clearly resulted in significant alterations in the transcrip-
tome of genes involved in retinoic acid metabolism. Re-
sponse to vitamin A and response to retinoic acid
metabolism were identified as key GO terms (Figure 2).
CYP2S1 depletion in BEAS-2B cells resulted in an over-
all down regulation of the RA metabolism compared to
scrambled control (Additional file 3). Many of the key
enzymes involved in metabolism of retinol were not
expressed in either CYP2S1 containing (SCRAM) or
CYP2S1 depleted BEAS-2B cells, including CYP26A1,
RPE65, and UGT2B7. CYP26A1 is the most efficient
metabolizing cytochrome P450 at oxidizing retinoic acid,
with affinity in the low nanomolar range [36]. CYP26B1
is the only CYP26 family expressed in BEAS-2B cellsand has demonstrated similar catalytic activity toward
RA [37-39]. RNA-seq data failed to demonstrate altered
CYP26B1 expression in response to CYP2S1 depletion.
Interestingly, upon closer inspection (Figure 3) we found
that other enzymes involved in converting retinal to RA
(i.e. AOX1) were significantly upregulated in CYP2S1
depleted cells, suggesting a metabolic flux possibly
resulting in elevated RA (Figure 3). Additionally, the lar-
gest increase in expression was observed in FABP5 (5.8
fold increase) suggesting that the retinoic acid flux may
be diverted into the PPAR signaling rather than meta-
bolic inactivation. However, experimental validation is
required to test these hypotheses.
Transcriptome analysis of arachidonic acid metabolism in
CYP2S1 depleted cells
CYP2S1 has been shown to metabolize products of the
two major metabolic pathways of the arachidonic acid
(AA) cascade, lipoxygenase and cyclooxygenase, in the
presence of lipid peroxides [22]. Fromel et al also dem-
onstrated CYP2S1-mediated epoxidation of a variety of
bioactive lipids including arachidonic acid to epoxyeico-
satrienoic acid (EETs) in sf-9 cells expressing CYP2S1
[9]. CYP2S1 depleted human BEAS-2B [23] and
monocyte-derived macrophages [9] show increased
levels of the inflammatory prostaglandin, PGE2. Con-
versely, over-expressing human CYP2S1 in rodent cells
reduced synthesis of products of the cyclooxygenase
pathway, PGE2 and PGD2 [22]. Based on published data,
as well changes in P450 expression (Table 2), we would
Figure 2 Top GO BP terms in CYP2S1 depleted human bronchial epithelial cells. The y-axis represents the top 30 biological processes and
the x-axis displays negative log2 P values. Analysis was restricted to 995 genes, representing p < 0.01 and at least 2-fold change in expression.
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metabolism in CYP2S1 depleted cells (759) compared to
controls (SCRAM). However, arachidonic acid metabol-
ism was not identified in the KEGG or GO terms. In
fact, the arachidonic acid GO term did not appear in our
most stringent (p < 0.01) criteria, but it did show up as
#175 when the p-value was relaxed (p < 0.05) (Additional
file 4). It is possible that the inability to detect transcrip-
tional changes within this pathway could suggest that ei-
ther: i) subtle transcriptional changes, undetected as
significantly different, in this pathway are sufficient to elicit
significant changes in AA metabolism, or ii) pathway ana-
lysis relies on a priori knowledge of AA metabolism, whichTable 2 Cytochrome P450s altered in CYP2S1 depleted cells
Altered in CYP2S1
depleted BEAS-2B
Fold change
& p value
Substrate
status
Evidence
CYP2S1 -3.2; p < 0.0001 Orphan Retinoic
CYP1A1 -3.6; p < 0.05 Xenobiotic Estrogen
CYP4Z1 4.2; p ≤ 0.05 Orphan Saturated
(C12:0, m
CYP4F11 2.7; p ≤ 0.001 Orphan Fatty Aci
CYP2J2 3.6; p < 0.05 Fatty Acid Arachidomay not be sufficient to clearly discern this pathway. These
data suggest that transcriptome analysis may underrepre-
sent potentially important pathways altered in response to
changes in CYP2S1 expression.
To determine the extent of regulation within the AA
pathway, we examined genes within the KEGG AA path-
way (Additional file 5). The main regulatory enzymes in
prostaglandin production (i.e. cyclooxygenase 2 (PTGS2)),
EET production (i.e. CYP2J2), and HETE production (i.e.
CYP4F11) are all significantly upregulated. In contrast, key
regulatory enzymes involved in the lipoxygenase pathway
(i.e. LOX) were not significantly altered. Closer examination
of the cyclooxygenase pathway (Figure 4) revealsfor endogenous substrate metabolism
acid [6,21,22]; prostaglandin metabolism [9,23]
, bilirubin, melatonin, arachidonic acid. Reviewed in [33]
and unsaturated fatty acid hydroxylation including lauric acid
yristic acid (C14:0); 11,14-eicosadienoic acid (C20:2); (C20:4) [31]
ds (w-2,-3, -4, -5) [25,32]
nic acid epoxidation to epoxyeicosatrienoic acids (EETS). Reviewed in [34]
Figure 3 The effects of CYP2S1 depletion on retinoic acid metabolism. A simplified version of genes involved in retinol metabolism,
focusing specifically on RA synthesis from retinol and retinal, RA metabolism through P450 oxidation and glucuronide conjugation, and RA
signaling through either PPAR or RAR mediated pathways. Grey indicates no significant change in expression. Gold represents very low
expression (i.e. base mean average value is <1.5). Shades of red and blue indicate a significant (p < 0.05) increase and decrease in expression in
CYP2S1 depleted cells, respectively. Numerical values represent fold change in RNA-seq. * indicates the significant (p < 0.05).
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prostaglandin, PGE2 production. Specifically, the enzyme
converting AA to PGG2 and PGH2 [COX-2 (PTGS2)] is
upregulated 2.4 fold. The prostaglandin synthase (PGES2)
is also slightly but significantly elevated (1.4 fold). In con-
trast, the PGE2 degrading enzyme, 15-PGDH, is reduced
by 2-fold. Transcriptional alterations within the cyclooxy-
genase pathway are consistent with elevated PGE2 levels
identified previously [23]. Therefore, it is possible that ana-
lysis of subsets from metabolic pathways may be required
to identify significant regulation.
RNA-sequencing analysis reveals a novel phenotype in
CYP2S1 depleted cells: differential regulation of cell size
To determine whether RNA-sequencing analysis could
reveal novel functions or phenotypes associated with an
orphan P450, we examined the literature for connections
between the top KEGG pathways. Three of the top regu-
lated pathways are involved in regulation of cell cycle,
growth factor signaling, and mTOR signaling. A com-
mon connection between each of these is the regulation
of cell size. In order to grow and divide, cells must
double their cellular contents (Reviewed in [42]).
CYP2S1 depleted BEAS-2B cells exhibit increased cell
proliferation [23]. Cell cycle control was listed as themost significant change in the KEGG classification. The
growth factor TGFβ, exhibits crosstalk with the mTOR
pathway [43]. mTOR pathway is recognized as a central
regulator in cell growth [26], and represents a potentially
novel CYP2S1-regulated pathway.
To probe which genes within the mTOR pathway were
altered in response to chronic CYP2S1 depletion, RNA
seq results for each gene in the mTOR signaling path-
way (according to the KEGG and SABioscience array)
were identified (Figure 5). A total of 24 out of 84 total
genes (29%), identified by the mTOR PCR array as key
regulated genes within the mTOR pathway, were identi-
fied through RNA sequencing as significantly altered
(p-adjusted < 0.05) between CYP2S1 depleted (759) and
scrambled controls (SCRAM). Regulation was similarly
divided between the elevated (9 genes accounting for
10% of the genes) and reduced expression (15 genes ac-
counting for 18% of the total). A total of 8 genes out of
the 84 (9.5%) genes exhibit at least a 2-fold change in ex-
pression when compared to ACTB: Downregulated
(5 genes: AKT1, EIF4EBP1, INSR, VEGFA, VEGFB); Up-
regulated (3 genes: DEPTOR, PRKAA2, and SGK1).
mTOR PCR array (SABioscience, Qiagen) was used to
validate transcriptional changes discovered by RNA-seq.
PCR array results were used to establish concordance
Figure 4 The effects of CYP2S1 depletion on arachidonic acid metabolism. A simplified version of the cyclooxygenase pathway within the
arachidonic acid metabolism pathway, focused on published cellular modulation of prostaglandin synthesis. Grey indicates no significant change
in expression. Gold represents very low expression (i.e. base mean average value is <1.5). Shades of red and blue indicate a significant (p < 0.05)
increase and decrease in expression in CYP2S1 depleted cells, respectively. Numerical values represent fold change in RNA-seq. * indicates the
significant (p <0.05).
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vs 984). A total of 84 regulated genes within the mTOR
pathway and five different housekeeping genes (B2M,
ACTB, GAPDH, HPRT1, and RPL13A) were quantified.
In order to compare results between RNA-seq and PCR
array, we identified ACTB as one housekeeping gene for
which expression was consistent between CYP2S1 de-
pleted cell lines (759 and 984) and scrambled controls
(SCRAM). Thus both RNA-seq and quantitative PCR ar-
rays were normalized to ACTB for comparison. The 24
genes exhibiting significant regulation are visualized
using a heat map (Figure 6). Among the 24 genes that
were significantly regulated, 19 out of 24 genes (80%)
were similarly regulated using the PCR array on CYP2S1
depleted (759); whereas, 17 out of 24 (71%) were simi-
larly regulated among CYP2S1 depleted (984). All of the
15 downregulated genes were confirmed using PCR
array in both 759 and 984 (Figure 6). Interestingly, the
upregulated genes did not demonstrate this concordance.
Only 4 and 2 genes out of 9 were similarly regulated in the
759 and 984, respectively. Interestingly, only PRKAA2 dem-
onstrated significant elevated expression between the two
shRNA targets. Overall, our data demonstrate a good con-
cordance between RNA seq and validation with qRT PCR
arrays.
Based on validated differences within the mTOR path-
way and significant changes in cell cycle and TGFβsignaling, alterations in cell size were assessed. To deter-
mine changes in cell diameter and volume, we utilized
the Millipore Scepter. Cells were cultured to approxi-
mately 80% confluence, trypsinized and counted. The
average cell diameter and volume of the CYP2S1 de-
pleted cell lines (759 and 984) and scrambled control
(SCRAM) were graphed (Figure 7). Interestingly CYP2S1
depleted cells exhibit a significant ~13% increase in
diameter (2 μM) and ~50% increase in volume (2pL).
This increase cannot be attributed to subclonal variation,
since two additional CYP2S1 depleted clones exhibit
similar increases in cell size when compared to two dis-
tinct SCRAM controls (data not shown).
Only one gene, eukaryotic initiation factor 4E binding
protein 1 (eIF4EBP1; log2 fold = -1.29, p < 0.001) met the
criteria of both statistical significance p < 0.05 and 2-fold
decrease in expression. eIF4EBP1 interacts with the transla-
tion initation factor eIF4E inhibiting the assembly of trans-
lation complex [44,45] The ratio of eIF4E/4E-BP is
important for controlling translation of eIF4E-sensitive
mRNA [46]. In this experiment, eIF4EBP1’s significant
downregulation would be consistent with an increase in cell
size in CYP2S1 depleted cells, since increased protein syn-
thesis is required for cell growth.
We propose that elevated PGE2 observed in response to
CYP2S1-mediated modulation of the cyclooxygenase path-
way [23], may stimulate the mTOR pathway to promote
Figure 5 The effects of CYP2S1 depletion on mTOR signaling. Heat map data transposed onto the KEGG mTOR signaling pathway. Grey
indicates no significant change in expression. Gold represents very low expression (i.e. base mean average value is <1.5). Shades of red and blue
indicate a significant (p < 0.05) increase and decrease in expression in CYP2S1 depleted cells, respectively. Numerical values represent fold change
in RNA-seq. * indicates the significant (p <0.05).
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phorylation and activation of Akt through the EP4 receptor
in prostate cancer cells [47]. Furthermore, mitogen-
stimulated activation of PI3K and Akt have been linked to
the activation of the mammalian target of rapamycin com-
plex I (mTORC1) [48]. mTORC1 kinase activity, in turn,
stimulates protein synthesis through the phosphorylation
and inactivation of eIF4EB-P. Further experimentation is
required to test whether CYP2S1-mediated changes in the
cyclooxygenase pathway [22,23], stimulating PGE2 synthe-
sis, is the pathway linking CYP2S1-mediated metabolism to
mTOR signaling and regulation of cell size in bronchial epi-
thelial cells.
Conclusions
The data presented in this article represent a novel
trancriptomic approach to identify the mode of action
for alterations in orphan P450 expression. Although, a
transcriptomic approach, alone, is not sufficient to
identify endogenous substrates, it can provide clues
into the biological significance of CYP2S1-mediated
metabolism, and/or compensation for these metabolicshifts. Moreover, it can shed light on potentially novel
important physiological pathways. Transcriptome find-
ings of CYP2S1 depleted cells are consistent with pre-
viously published cellular phenotypes [23]. The results
also identified differential expression of genes in-
volved in the mTOR pathway, a master regulator of
cell size, which resulted in the identification of a
novel, measurable phenotype (specifically, increase in
cell size) in CYP2S1-depleted cells. Additionally, tran-
scriptomic analysis was consistent with proposed en-
dogenous lipid substrates as well as compensatory
metabolic shifts in CYPs involved in lipid metabolism.
Although this approach provides an excellent way of
examining mode of action, it fails to identify specific
chemical substrates and metabolic products. Con-
versely, a metabolomic approach identifies the metab-
olites but does not establish the physiological impact.
Ultimately, a multi-omic approach integrating both
transcriptomic and metabolomic analysis, may provide
a powerful predictive approach to elucidate endogen-
ous substrates as well as biological significance of or-
phan P450’s.
Figure 6 Concordance between RNA seq and quantitative PCR
array within genes of the mTOR signaling pathway. A subset of
84 genes from the mTOR PCR array is compared between shRNA
targets (759 and 984) and methodologies (i.e. RNA-seq and PCR
array) using a heat map. Grey indicates no significant change in
expression. Gold represents very low expression (i.e. base mean
average value is <1.5). Shades of red and blue indicate a significant
(p < 0.05) increase and decrease in expression in CYP2S1 depleted
cells, respectively. All colored genes except grey indicate significant
increases in RNA seq, p < 0.05.
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RNA isolation
As indicated in our previous publication [23] we used
the clones with the most significant difference in
CYP2S1 expression for RNA-sequencing analysis (i.e.Figure 7 Quantification and comparison of BEAS-2B cell diameter and
depleted cells (759 and 984) vs. scrambled (SCRAM) control. ***, **, and * rSCRAM#1 and 759#7). BEAS-2B CYP2S1 depleted cells
(759 and 984) and scrambled controls (SCRAM) cells
were grown in a six well plates to confluence and
washed with PBS. RNA was isolated according to the
manufactures protocol (Qiagen RNeasy) and eluted in
20ul of RNAse-free water. RNA quality was analyzed
using the Bioanalyzer (Agilent 2100 Bioanalyzer with
Agilent RNA 6000 Nano reagents) and samples with
RNA integrity number (RIN) between 9 and 10 were
sent to the National Center for Genomics Research
(NCGR, Santa Fe, NM) for Illumina RNA sequencing or
stored for qRT-PCR validation. In total, 3 biological
replicates from each genotype (759#7, 984#1, and
SCRAM#1) were assessed.
Library preparation and sequencing
Messenger RNA for 759 and SCRAM samples was isolated
from total RNA samples with polyA selection, size selected
and prepared into sequencing libraries with the TruSeq
RNA sample preparation workflow from Illumina (San
Diego, CA). Libraries were sequenced on the Illumina
HiSeq 2000 platform, generating 141,896,712 1×50 nt
single-end reads, averaging 11,824,726 reads per sample.
Raw Illumina reads are available at the Sequence Read
Archive at NCBI under the accession: SUB278513.
Read count based expression
For each sample, raw sequence reads were filtered and
aligned to the human reference genome (GRCh37) with
GSNAP [49]. Subsequent management of the data was
performed by Alpheus [50]. Reads that aligned unambigu-
ously to the human reference were binned based on
annotated gene coordinates and summated to estimate
expression level. Read count based expression estimates
were evaluated for transcriptome-wide qualitativevolume. A. Average cell diameter (μM) and B. volume (pL) in CYP2S1
epresent p values p < 0.001, p < 0.01, and p < 0.05, respectively.
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tial gene expression analysis was performed with the nega-
tive binomial test as implemented in the Bioconductor
package DESeq [27]. Genes were identified as differentially
expressed if they had an adjusted (Benjamini-Hochberg
False Discovery Rate (FDR) method for multiple testing
correction) p-value of 0.05 or less.Quantitative PCR analysis
cDNA was synthesized, using iScript reverse transcrip-
tion supermix (BioRad, Hercules, CA), from 1 μg total
RNA. Quantitative qRT-PCR was conducted using IQ
sybr green supermix (BioRad) in accordance with manu-
facturers instructions, and performed using the BioRad
CFX96. Primer efficiencies were calculated using stand-
ard curves obtained from plasmid-based amplicons. The
housekeeping gene ACTB was selected based on
consistency between samples, and samples were normal-
ized to its expression. The qRT-PCR primers used as
previously described [23].Pathway and functional analysis of differentially
expressed genes
To gain biological insight and contextualized differen-
tially expressed genes (as described above), we further
analyzed genes that were significantly altered with ad-
justed p-values of either <0.001 or <0.01. These subsets
included 1579 and 2766 total genes, respectively. The
open source database for annotation, visualization and
integrated discovery (DAVID version 6.7) [28,29] was
employed to assess biological function of the selected
genes. The functional annotation tool was used to clus-
ter genes based on the degree of association. Functional
annotation was set at high stringency and restricted to
groups with an enrichment score greater than or equal
to 1.3. Gene ontology (GO) terms and KEGG pathway
were reported. Functional annotation tool is mainly pro-
vided the most relevant gene ontology terms (GO terms)
associated with the gene list and we reported the mostly
enriched GO term, which is GOTERM_BP_FAT. Add-
itionally we looked into highly affected KEGG pathways
with the gene list submitted.Cell size determination
BEAS-2B cells were grown in 6 well plates to approxi-
mately 80% confluence, trypsinized, and cell diameter
and volume were quantified using the Millipore scepter
automated cell counter. Trypsinized cellular populations
were gated between 10-24 μM to ensure that in-tact
cells were identified. The final cell size represents the
average cell size from a total of six biological replicates
from each genotype.PCR pathway array
The human mTOR RT profiler PCR pathway array
(SABioscience Qiagen, Cat.no.330231 PAHS-098ZD) was
used to validate mTOR regulation identified through RNA
seq. RNA was isolated and analyzed as indicated above.
cDNA was synthesized (Qiagen, RT first strand kit) and the
PCR array was performed according to the manufactures
protocol (Qiagen, Cat.no. 330231 PAHS-098ZD). PCR was
run on the BIORAD CFX96 real-time cycler and data was
analyzed using SABiosciences Excel based PCR array data
analysis template (http://www.sabiosciences.com/pcrarray-
dataanalysis.php). The threshold cycle (CT) values, obtained
through PCR, were exported to the SABiosciences Excel
template. The ΔCT was calculated for each gene in relation
to house keeping genes and ΔΔCT was calculated relative
to the control sample (SCRAM). Based on the ΔΔCT values
fold change (2(-ΔΔCT)) was reported.
Additional files
Additional file 1: The list of all genes identified in CYP2S1 depleted
(759) and SCRAM BEAS-2B cells. This is based on read count
expression. The differentially expressed genes identified if they had an
adjusted (Benjamini-Hochberg False Discovery Rate (FDR) method for
multiple testing correction) p-value of 0.05 or less.
Additional file 2: Complete GO BP function annotation results of
995 differentially expressed genes. These genes exhibit a 2-fold
change in expressions that were consistently either up or down-
regulated between biological replicates (p < 0.01).
Additional file 3: Differential expressed genes in Retinol
metabolism. Differential gene expression is indicated on the KEGG
pathway. Grey indicates no significant change in expression. Gold
represents very low expression (i.e. base mean average value is <1.5).
Shades of red and blue indicate a significant (p < 0.05) increase and
decrease in expression in CYP2S1 depleted cells, respectively. All colored
genes except grey indicate significant increases in RNA seq, p < 0.05.
Additional file 4: Complete GO BP function annotation results of
4516 differentially expressed genes. These genes expressions were
consistent between biological replicates (p < 0.05).
Additional file 5: Differential expressed genes in Arachidonic Acid
metabolism. Differential gene expression is indicated on the KEGG
pathway. Grey indicates no significant change in expression. Gold
represents very low expression (i.e. base mean average value is <1.5).
Shades of red and blue indicate a significant (p < 0.05) increase and
decrease in expression in CYP2S1 depleted cells, respectively. All colored
genes except grey indicate significant increases in RNA seq, p < 0.05.
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